The patentability of software in the US
12 November 2024
We are lucky to share with you insights from our New York patent experts Charles Wizenfeld, Michael S.
Read on
Suzy Madar
Proposed modifications to the regulation of gene technology in Australia
4 November 2024
The Department of Health and Aged Care is proposing the first major amendments to the Gene Technology Act 2000 (Cth) (the Act) since its commencement.
Read on
The mRNA patent wars: lessons for businesses & organisations who rely on patent rights
28 October 2024
Two weeks ago, GlaxoSmithKline (GSK) filed proceedings against the makers of the COVID-19 SPIKEVAX® vaccine, Moderna, Inc in the US Federal District Court in Delaware alleging that Moderna has infringed its patents relating to messenger RNA (mRNA) technology.
Read on
IPO 2018: Insights from the USPTO, EPO and the bench (when digital natives meet digital immigrants)
28 September 2018
The Intellectual Property Owners Association’s 46th Annual Meeting took place in Chicago from 23 to 25 September 2018.
Read on
United States FDA gets serious about biosimilars
5 September 2018
The most significant advances in medical treatments are being made with biological products.
Read on
Fast drugs, new drugs: new opportunities in the healthcare industry in Australia and China
27 April 2018
Chinese and Australian businesses looking for overseas opportunities to expand in the healthcare industry should be aware of important regulatory changes that are taking place in both China and Australia.
Read on
Second throw of the dice unsuccessful: Full Federal Court confirms Hepatitis C drug patent is invalid
21 December 2017
The recent decision of the Full Court in Idenix Pharmaceuticals v Gilead Sciences [2017] FCAFC 196 illustrates the power of the grounds of lack of utility and lack of sufficiency under section 40 of the Patents Act when challenging the validity of a patent.
Read on
Biosimilars: balancing access to affordable medicines with safety
3 November 2017
Biological medicines (biologics) are agents derived from a biological source.
Read on
Full Court warns against dangerous affliction of parameteritis (and confirms invalidity of aripiprazole patent)
26 August 2016
On Wednesday the Full Court of the Federal Court of Australia handed down a decision in which it upheld Justice Yates’ findings that Otsuka’s patent relating to aripiprazole, a drug used in the treatment of schizophrenia, is invalid for want of novelty and inventive step.
Read on
Next steps after Australia China Free Trade Agreement – how to make the most of the opportunity
23 July 2015
The China-Australia Free Trade Agreement represents significant opportunities for Australian health and aged care providers.
Read on
Load More Posts